How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications

Airdate: Thursday, April 25, 2024 Season: 3 Episode: 9

Guest: Joseph Zabinski

Sponsor: OM1

In this episode of tHEORetically Speaking, Dr. Joseph Zabinksi, VP and Head of Commercial Strategy and AI at OM1, explains how AI-powered digital phenotyping can enhance our understanding of patients’ experiences and inform access, treatment, and condition management.

Real-world data provides an opportunity to understand what happens to patients, but there are limitations to the insights we can generate using traditional analysis techniques alone. At OM1, our PhenOM technology uses AI to isolate subtle signals in real-world data associated with outcomes we care about – diagnoses, treatment response, and future risks. The insights we derive integrate into our existing patient journeys to answer questions we couldn’t without this technology, including who remains undiagnosed or misdiagnosed, and how patient subcohorts take different trajectories within the same broader condition.

OM1 is an insights-driven technology and data company specializing in Personalized Medicine, Evidence Generation, and RWE Research powered by next-Gen AI platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership. Our unprecedented innovation takes RWE from Bench-to-Practice, delivering unparalleled personalized impact on the outcomes of patients and the advancement of research.

Want to learn more about OM1 PhenOM? Send a message to: info@om1.com.

Having trouble viewing the player? Click here to listen to the episode.

Similar Podcasts

How AI Can Help Dermatology: Diagnosis, Treatment, Risk, and R&D

The hype around AI is finally translating into real-world value, and we are seeing broader adoption of real-world data in Dermatology. This episode of tHEORetically Speaking features Dr. Stefan Weiss, Managing Director of Dermatology and Dr. Joseph Zabinski, Managing Director of AI and Personalized Medicine at OM1, who discuss the path to personalized medicine and AI-powered clinical decision support in dermatology.

The Sooner, the Better: Detecting and Decoding Alzheimer’s with Real-World Data

The landscape for Alzheimer’s disease is rapidly changing. This episode of tHEORetically speaking features Dr. Carl Marci from OM1 and Dr. Luke Stoeckel from NIA, as they discuss the critical need for earlier detection leading to potentially life changing earlier interventions.

Leveraging Real-World Data for Precision Obesity Treatment

Today’s episode of tHEORetically speaking features Gary Curhan, Chief Medical Officer and Jessica Paulus, Vice President of Research at OM1, as they answer questions on Leveraging Real-World Data for Precision Obesity Treatment.